Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Breathe Biologics

breathebiologics.com ↗

Clinical Phase 3

Keywords: respiratory pulmonary disease Acute Respiratory Distress Syndrome

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Mar 1, 2027 Trial start Phase 3: To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory D source ↗

Upcoming milestones

Oct 31, 2027 (ESTIMATED) · Phase 3 · To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress S · NCT07479043

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07479043	To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).	Phase 3	Not yet recruiting	Mar 1, 2027	Oct 31, 2027 (estimated)